Relevant Issues in the Monitoring and the Toxicology of Antidepressants

REFERENCES

• Uges D RA, Conemans J MH. ADs and antipsychotics. Forensic Science. Handbook of Analytical Separations, M. J. Bogusz. Elsevier Science, Amsterdam 2000; 229–256
   Google Scholar
• Sampson S M. Treating depression with selective serotonin reuptake inhibitors: a practical approach. Mayo Clin Proc 2001; 76: 739–744
   PubMed Web of Science ®Google Scholar
• World health organization. WHO, http://www.who.int/mental_health
   Google Scholar
• Nestler E J, Barrot M, DiLeone R J, Eisch A J, Gold S J, Monteggia L M. Neurobiology of depression. Neuron 2002; 34: 13–25
   PubMed Web of Science ®Google Scholar
• Taylor C, Fricker A D, Devi L A, Gomes N. Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal 2005; 17: 549–557
   PubMed Web of Science ®Google Scholar
• Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76: 511–527
   PubMed Web of Science ®Google Scholar
• Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 2003; 64: 5–12, (Suppl 13)
   PubMed Web of Science ®Google Scholar
• Schwaninger M, Weisbrod M, Knepel W. Progress in defining the mechanism of action of antidepressants—across receptors and into gene transcription. CNS Drugs 1997; 8: 237–243
   Web of Science ®Google Scholar
• Malberg J E, Blendy J A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005; 26: 631–638
   PubMed Web of Science ®Google Scholar
• Yildiz A, Gönül A, Tamam L. Mechanism of actions of antidepressants: beyond the receptors. Bull Clin Psychopharmacol 2002; 12: 194–200
   Google Scholar
• Dwivedi Y, Rizavi H S, Conley R R, Roberts R C, Tamminga C A, Pandey G N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804–815
   PubMed Web of Science ®Google Scholar
• Vetulani J, Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol 2000; 405: 351–363
   PubMed Web of Science ®Google Scholar
• Kent J M. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911–918
   PubMed Web of Science ®Google Scholar
• Pacher P, Kohegyi E, Kecskemeti V, Furst S. Current trends in the development of new antidepressants. Curr Med Chem 2001; 8: 89–100
   PubMed Web of Science ®Google Scholar
• Kent J. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 2000
   Web of Science ®Google Scholar
• Mann J J. Drug therapy—The medical management of depression. N Engl J Med 2005; 353: 1819–1834
   PubMed Web of Science ®Google Scholar
• Vanharten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203–220
   PubMed Web of Science ®Google Scholar
• Masand P S, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999; 7: 69–84
   PubMed Web of Science ®Google Scholar
• Rudorfer M V, Potter W Z. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol 1999; 19: 373–409
   PubMed Web of Science ®Google Scholar
• Sproule B A, Naranjo C A, Bremner K E, Hassan P C. Selective serotonin reuptake inhibitors and CNS drug interactions—A critical review of the evidence. Clin Pharmacokinet 1997; 33: 454–471
   PubMed Web of Science ®Google Scholar
• Nemeroff C B, DeVane C L, Pollock B G. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311–320
   PubMed Web of Science ®Google Scholar
• Stahl S M. Mechanism of action of serotonin selective reuptake inhibitors—serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215–235
   PubMed Web of Science ®Google Scholar
• Boyer W F, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112–1119
   PubMed Web of Science ®Google Scholar
• Harrigan R A, Brady W J. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 1999; 17: 387–393
   PubMed Web of Science ®Google Scholar
• Hardman J, Limberd L, Molinoff P, Ruddon R. Goodman and Gilman's the pharmacological basis of therapeutics. Goodman and Gilman's the pharmacological basis of therapeutics 9th Ed., A Goodman Gilman. McGraw-Hill, New York 1996; 1905
   Google Scholar
• Glauser J. Tricyclic antidepressant poisoning. Cleve Clin J Med 2000; 67: 704–706
   PubMed Web of Science ®Google Scholar
• Kerr G W, McGuffie A C, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J 2001; 18: 236–241
   PubMed Web of Science ®Google Scholar
• Thanacoody H K, Thomas S H. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol. Rev. 2005; 24: 236–241
   Google Scholar
• Cohen H W, Gibson G, Alderman M H. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am J Med 2000; 108: 2–8
   PubMed Web of Science ®Google Scholar
• Roose S P. Treatment of depression in patients with heart disease. Biol Psychiatry 2003; 54: 262–268
   PubMed Web of Science ®Google Scholar
• Ray W A, Meredith S, Thapa P B, Hall K, Murray K T. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234–241
   PubMed Web of Science ®Google Scholar
• Denollet J, Sys S U, Stroobant N, Rombouts H, Gillebert T C, Brutsaert D L. Personality as independent predictor of long-term mortality in patients with coronary heart disease. Lancet 1996; 347: 417–421
   PubMed Web of Science ®Google Scholar
• Glassman A H. Cardiovascular effects of antidepressant drugs: Updated. Int Clin Psychopharmacol 1998; 13: S25–S30
   PubMed Web of Science ®Google Scholar
• Roose S P. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000; 140: 584–588
   Web of Science ®Google Scholar
• Roose S P. Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. J Clin Psychiatry 2001; 62: 19–23
   PubMed Web of Science ®Google Scholar
• Glassman A H. Cardiovascular effects of antidepressant drugs: Updated. J Clin Psychiatry 1998; 59: 13–18
   PubMed Web of Science ®Google Scholar
• Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28
   PubMed Web of Science ®Google Scholar
• Cipriani A, Barbui C, Geddes J R. Suicide, depression, and antidepressants. BMJ 2005; 330: 373–374
   PubMed Web of Science ®Google Scholar
• Licinio J, Wong M L. Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 2005; 4: 165–171
   PubMed Web of Science ®Google Scholar
• Whittington C J, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–1345
   PubMed Web of Science ®Google Scholar
• Goldstein D J, Sundell K. A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Hum Psychopharmacol 1999; 14: 319–324
   Web of Science ®Google Scholar
• Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28: 137–152
   PubMed Web of Science ®Google Scholar
• Sanz E J, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365: 482–487
   PubMed Web of Science ®Google Scholar
• Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005; 365: 451–453
   PubMed Web of Science ®Google Scholar
• Scoggins B A, Maguire K P, Norman T R, Burrows G D. Measurement of tricyclic anti-depressants.1. review of methodology. Clin Chem 1980; 26: 5–17
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Kanba S, Kubo H, Yagi G, Iri H, Yuki H. Automated-determination of drugs in serum by column-switching high-performance liquid-chromatography. 4. Separation of tricyclic and tetracyclic antidepressants and their metabolites. Clin Chem 1989; 35: 453–456
   PubMed Web of Science ®Google Scholar
• Caldwell R, Challenger H. A capillary column gas-chromatographic method for the identification of drugs of abuse in urine samples. Ann Clin Biochem 1989; 26: 430–443
   PubMed Web of Science ®Google Scholar
• Demedts P, Wauters A, Franck F, Neels H. Evaluation of the Remedi(r) drug profiling system. Eur J Clin Chem Clin Biochem 1994; 32: 409–417
   PubMedGoogle Scholar
• Theurillat R, Thormann W. Monitoring of tricyclic antidepressants in human serum and plasma by HPLC: characterization of a simple, laboratory developed method via external quality assessment. J Pharm Biomed Anal 1998; 18: 751–760
   PubMed Web of Science ®Google Scholar
• Lacassie E, Gaulier J M, Marquet P, Rabatel J F, Lachatre G. Methods for the determination of seven selective serotonin reuptake inhibitors and three active metabolites in human serum using high-performance liquid chromatography and gas chromatography. J Chromatogr B Biomed Sci Appl 2000; 742: 229–238
   PubMed Web of Science ®Google Scholar
• Goeringer K E, McIntyre I M, Drummer O H. LC-MS analysis of serotonergic drugs. J Anal Toxicol 2003; 27: 30–35
   PubMed Web of Science ®Google Scholar
• Ruiz-Angel M J, Carda-Broch S, Simo-Alfonso E F, Garcia-Alvarez-Coque M C. Optimised procedures for the reversed-phase liquid chromatographic analysis of formulations containing tricyclic antidepressants. J Pharm Biomed Anal 2003; 32: 71–84
   PubMed Web of Science ®Google Scholar
• Frahnert C, Rao M L, Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 794: 35–47
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hidaka K, Ishida J, Yoshikuni K, Nohta H, Yamaguchi M. Highly selective and sensitive determination of tricyclic antidepressants in human plasma using high-performance liquid chromatography with post-column tris(2,2′-bipyridyl) ruthenium(III) chemiluminescence detection. Anal Chim Acta 2000; 413: 137–145
   Web of Science ®Google Scholar
• Ivandini T A, Sarada B V, Terashima C, Rao T N, Tryk D A, Ishiguro H, Kubota Y, Fujishima A. Electrochemical detection of tricyclic antidepressant drugs by HPLC using highly boron-doped diamond electrodes. J Electroanal Chem 2002; 521: 117–126
   Web of Science ®Google Scholar
• Kollroser M, Schober C. Simultaneous determination of seven tricyclic antidepressant drugs in human plasma by direct-injection HPLC-APCI-MS-MS with an ion trap detector. Ther Drug Monit 2002; 24: 537–544
   PubMed Web of Science ®Google Scholar
• Eap C B, Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. J Chromatogr B Biomed Appl 1996; 686: 51–63
   PubMed Web of Science ®Google Scholar
• Goeringer K E, Raymon L, Christian G D, Logan B K. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: A review of pharmacology and report of 168 cases. J Forensic Sci 2000; 45: 633–648
   PubMed Web of Science ®Google Scholar
• Cox R, Crifasi J, Dickey R, Ketzler S, Pshak G. A single step extraction for screening whole blood for basic drugs by capillary GC/NPD. J Anal Toxicol 1989; 13: 224–228
   PubMed Web of Science ®Google Scholar
• Demedts P, Neels H, Maes M, Dai J, Ranjan R, Melzer H. Effects of fluoxetine on serum mCPP concentration in depressed patients. Ther Drug Monit 1995; 17: 390
   Google Scholar
• Gupta R N. Drug level monitoring-antidepressants. J Chromatogr 1992; 576: 183–211
   PubMed Web of Science ®Google Scholar
• Baumann P, Zullino D F. C.B. E. Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433–444
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Raggi M A. Advances in the enantioseparation of second-generation antidepressant drugs by electrodriven methods. Electrophoresis 2006; 27: 213–221
   PubMed Web of Science ®Google Scholar
• Decision Resources Inc. The Antidepressant Market through 2014—Focus on emerging therapies and new indications. Cognos Plus Study 2005; 11: 176
   Google Scholar
• TIAFT. The international association of forensic toxicologists, http://www.tiaft.org/ Tiaft bulletin26 1S
   Google Scholar
• Council of the Royal Pharmaceutical Society of Great Britain. Martindale -The extra Pharmacopoeia. Martindale -The extra Pharmacopoeia, K. Parfitt, A. V. Parsons, S. C. Sweetman. The Pharmaceutical Press, London 1993; 2363
   Google Scholar
• Moffat A C, Osselton M D, Widdop B. Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material, 3th Ed., Y. G. Laurent. Pharmaceutical Press, London 2004; 1935
   Google Scholar
• Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP219 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376–385
   PubMed Web of Science ®Google Scholar
• FDA, http://www.fda.gov
   Google Scholar
• Lawson K. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?. Expert Opin Investig Drugs 2002; 11: 1437–1445
   PubMed Web of Science ®Google Scholar
• Hall E J, Sykes N P. Analgesia for patients with advanced disease: 2. Postgrad Med J 2004; 80: 190–195
   PubMedGoogle Scholar
• Glazener C M, Evans J H, Peto R E. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev 2003; 3, CD002117
   Google Scholar
• Owens M J, Nemeroff C B. Role of serotonin in the pathophysiology of sepression—focus on the serotonin transporter. Clin Chem 1994; 40: 288–295
   PubMed Web of Science ®Google Scholar
• Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467–489
   PubMed Web of Science ®Google Scholar
• Garland W A. Quantitative determination of amitriptyline and its principal metabolite, nortiptyline, by GLC-chemical ionization mass spectrometry. J Pharm Sci 1977; 66: 77–81
   PubMed Web of Science ®Google Scholar
• Edelbroek P M, Zitman F G, Schreuder J N, Rooymans H GM, Dewolff F A. Amitriptyline metabolism in relation to antidepressive effect. Clin Pharmacol Ther 1984; 35: 467–473
   PubMed Web of Science ®Google Scholar
• Bock J L, Giller E, Gray S, Jatlow P. Steady-state plasma-concentrations of cis- and trans-10-OH amitriptyline metabolites. Clin Pharmacol Ther 1982; 31: 609–616
   PubMed Web of Science ®Google Scholar
• Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50: 1623–1633
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, Baettig D, Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350–358
   PubMed Web of Science ®Google Scholar
• Karkkainen S, Neuvonen P. Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH. Int J Clin Pharmacol Ther Toxicol 1986; 24: 326–332
   PubMed Web of Science ®Google Scholar
• Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003; 58: 447–474
   PubMed Web of Science ®Google Scholar
• Corona G L, Cucchi M L, Frattini P, Santagostino G, Schinelli S, Zerbi F, Savoldi F. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression. Psychopharmacology 1990; 100: 334–338
   PubMed Web of Science ®Google Scholar
• Scoggins B A, Maguire K P, Norman T R, Burrows G D. Measurement of tricyclic anti-depressants. Part II. Applications of methodology. Clin Chem 1980; 26: 805–815
   PubMed Web of Science ®Google Scholar
• Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393–396
   PubMed Web of Science ®Google Scholar
• Wong S HY. Measurement of antidepressants by liquid-chromatography—a review of current methodology. Clin Chem 1988; 34: 848–855
   PubMed Web of Science ®Google Scholar
• Segatti M P, Nisi G, Grossi F, Mangiarotti M, Lucarelli C. Rapid and simple high-performance liquid-chromatographic determination of tricyclic antidepressants for routine and emergency serum analysis. J Chromatogr 1991; 536: 319–325
   PubMed Web of Science ®Google Scholar
• Couper F J, McIntyre I M, Drummer O H. Detection of antidepressant and antipsychotic-drugs in postmortem human scalp hair. J Forensic Sci 1995; 40: 87–90
   PubMed Web of Science ®Google Scholar
• Kudo K, Jitsufuchi N, Imamura T. Selective determination of amitriptyline and nortriptyline in human plasma by HPLC with ultraviolet and particle beam mass spectrometry. J Anal Toxicol 1997; 21: 185–189
   PubMed Web of Science ®Google Scholar
• Hackett L P, Dusci L J, Ilett K F. A comparison of high-performance liquid chromatography and fluorescence polarization immunoassay for therapeutic drug monitoring of tricyclic antidepressants. Ther Drug Monit 1998; 20: 30–34
   PubMed Web of Science ®Google Scholar
• Bailey D N, Jatlow P I. Gas-chromatographic analysis for therapeutic concentrations of amitriptyline and nortriptyline in plasma, with use of a nitrogen detector. Clin Chem 1976; 22: 777–781
   PubMed Web of Science ®Google Scholar
• de l a, Torre R, Ortuno J, Pascual J, Gonzalez S, Ballesta J. Quantitative determination of tricyclic antidepressants and their metabolites in plasma by solid-phase extraction (Bond-Elut TCA) and separation by capillary gas chromatography with nitrogen-phosphorous detection. Ther Drug Monit 1998; 20: 340–346
   PubMed Web of Science ®Google Scholar
• Tracey J A, Cassidy N, Casey P B, Ali I. Bupropion (Zyban) toxicity. Ir Med J 2002; 95: 23–24
   PubMedGoogle Scholar
• Xu H, Loboz K K, Gross A S, McLachlan A J. Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality 2007; 19: 163–170
   PubMed Web of Science ®Google Scholar
• Foley D F, DeSanty K P, Kast R E. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006; 6: 1249–1265
   PubMed Web of Science ®Google Scholar
• Dwoskin L P, Rauhut A S, King-Pospisil K A, Bardo M T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006; 12: 178–207
   PubMedGoogle Scholar
• Lai A A, Schroeder D HJ. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 1983; 44: 82–84
   PubMed Web of Science ®Google Scholar
• Jefferson J W, Pradko J F, Muir K T. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005; 27: 1685–1695
   PubMed Web of Science ®Google Scholar
• Hesse L M, Venkatakrishnana K, Court M H, Von Moltke L L, Duan S X, Shader R I, Greenblatt D J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28: 1176–1183
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger U M, Murdter T E, Roots I, Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003; 13: 619–626
   PubMedGoogle Scholar
• Laizure S C, DeVane C L, Stewart J T, Dommisse D S, Lai A A. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985; 38: 586–589
   PubMed Web of Science ®Google Scholar
• Goodnick P J. Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull. 1991; 27: 513–519
   PubMedGoogle Scholar
• DeVane C L, Laizure S C, Stewart J T, Kolts B E, Ryerson E G, Miller R L, Lai A A. Disposition of bypropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990; 27: 513–519
   Google Scholar
• Preskorn S H. Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 1983; 44: 137–139
   PubMed Web of Science ®Google Scholar
• Fogel P, Mamer O A, Chouinard G, Farrell P G. Determination of plasma bupropion and its relationship to therapeutic effect. Biomed Mass Spectrom 1984; 11: 629–632
   PubMedGoogle Scholar
• Ames D, Wirshing W C, Szuba M P. Organic mental disorders associated with bupropion in three patients. J Clin Psychiatry 1992; 53: 53–55
   PubMed Web of Science ®Google Scholar
• Settle E C, Stahl S M, Batey S R, Johnston J A, Ascher J A. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21: 454–463
   PubMed Web of Science ®Google Scholar
• Tutka P, Mroz T, Klucha K, Piekarczyk M, Wielosz M. Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res 2005; 64: 13–22
   PubMed Web of Science ®Google Scholar
• Shepherd G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy 2005; 25: 1378–1382
   PubMed Web of Science ®Google Scholar
• Spiller H A, Ramoska E A, Krenzelok E P, Sheen S R, Borys D J, Villalobos D, Muir S, Jones-Easom L. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994; 12: 43–45
   PubMed Web of Science ®Google Scholar
• Druteika D, Zed P J. Cardiotoxicity following bupropion overdose. Ann Pharmacother 2002; 36: 1791–1795
   PubMed Web of Science ®Google Scholar
• Belson M G, Kelley T R. Bupropion exposures: clinical manifestations and medical outcome. J Emerg Med 2002; 23: 223–230
   PubMed Web of Science ®Google Scholar
• Balit C R, Lynch C N, Isbister G K. Bupropion poisoning: a case series. Med J Aust 2003; 178: 61–63
   PubMed Web of Science ®Google Scholar
• Isbister G K, Balit C R. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 2003; 37: 999–1002
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Brauer L HTT.S., Hatsukami D KHJ., Bronars C A, Adson D E. Inhibition of CYPD6 activity by bupropion. J Clin Phsychopharmacol 2005; 25: 226–229
   PubMed Web of Science ®Google Scholar
• Ketter T A, Jenkins J BS, Schroeder D H, Pazzaglia P J, Marangell L B, George M S, Callahan A M, Hinton M L, Chao J, Post R M. Carbamazepine but not valproate induces bupropion metabolism. J Clin Phsychopharmacol 1995; 15: 327–333
   PubMed Web of Science ®Google Scholar
• Hogeland G W, Swindells S, McNabb J C, Kashuba A D, Yee G C, Lindley C M. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007; 81: 69–75
   PubMed Web of Science ®Google Scholar
• Cooper T B, Suckow R F, Glassman A. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J Pharm Sci 1984; 73: 1104–1107
   PubMed Web of Science ®Google Scholar
• Jennison T A, Brown P, Crossett J, Urry F M. A high-performance liquid chromatographic method for quantitating bupropion in human plasma or serum. J Anal Toxicol 1995; 19: 69–72
   PubMed Web of Science ®Google Scholar
• Suckow R F, Zhang M F, Cooper T B. Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography. Biomed Chromatogr 1997; 11: 174–179
   PubMed Web of Science ®Google Scholar
• Loboz K K, Gross A S, Ray J, McLachlan A J. HPLC assay for bupropion and its major metabolites in human plasma. J Chromatogr B Biomed Sci Appl 2005; 823: 115–121
   PubMed Web of Science ®Google Scholar
• Borges V, Yang E, Dunn J, Henion J. High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column. J Chromatogr B Biomed Sci Appl 2004; 804: 277–287
   PubMed Web of Science ®Google Scholar
• Rohrig T P, Ray N G. Tissue distribution of bupropion in a fatal overdose. J Anal Toxicol 1992; 16: 343–345
   PubMed Web of Science ®Google Scholar
• Bezchlibnyk-Butler K, Aleksic I, Kennedy S H. Citalopram–a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000; 25: 241–256
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso K P, Ebert B, Reines E H, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004; 174: 163–176
   PubMed Web of Science ®Google Scholar
• Kennedy S HH.F. A, Lam R W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122–131
   PubMed Web of Science ®Google Scholar
• Brosen K, Naranjo C. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11: 275–283
   PubMed Web of Science ®Google Scholar
• Le Bloc'h Y, Woggon B, Weissenrieder H, Brawand-Amey M, Spagnoli J, Eap C B, Baumann P. Routine therapeutic drug monitoring in patients treated with 10–360 mg/day citalopram. Ther Drug Monit 2003; 25: 600–608
   PubMed Web of Science ®Google Scholar
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Kuss H J, Laux G, Müller-Oerlinghausen B, Rao M L, Riederer P, Zernig G. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243–265
   PubMed Web of Science ®Google Scholar
• Rochat B, Amey M, Gillet M, Meyer U A, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7: 1–10
   PubMedGoogle Scholar
• Caccia S. Metabolism of the newer antidepressants—An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34: 281–302
   PubMed Web of Science ®Google Scholar
• Barak Y, Swartz M, Levy D, Weizman R. Age-related differences in the side effect profile of citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 545–548
   PubMed Web of Science ®Google Scholar
• Joubert A F, Sanchez C, Larsen F. Citalopram. Hum Psychopharmacol 2000; 15: 439–451
   PubMed Web of Science ®Google Scholar
• Dams R, Benijts T HP, Lambert W E, Van Bocxlaer J F, Van Varenbergh D, Peteghem C V, De Leenheer A P. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 2001; 25: 147–151
   PubMed Web of Science ®Google Scholar
• Jonasson B, Saldeen T. Citalopram in fatal poisoning cases. Forensic Sci Int 2002; 126: 1–6
   PubMed Web of Science ®Google Scholar
• Andersen S, Halvorsen T G, Pedersen-Bjergaard S, Rasmussen K E, Tanum L, Refsum H. Stereospecific determination of citalopram and desmethylcitalopram by capillary electrophoresis and liquid-phase microextraction. J Pharm Biomed Anal 2003; 33: 263–273
   PubMed Web of Science ®Google Scholar
• Singh S S, Shah H, Gupta S, Jain M, Sharma K, Thakkar P, Shah R. Liquid chromatography-electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study. J Chromatogr B Biomed Sci Appl 2004; 811: 209–215
   PubMed Web of Science ®Google Scholar
• Rasmussen B B, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. Ther Drug Monit 2000; 22: 143–154
   PubMed Web of Science ®Google Scholar
• Zheng Z C, Jamour M, Klotz U. Stereoselective HPLC-assay for citalopram and its metabolites. Ther Drug Monit 2000; 22: 219–224
   PubMed Web of Science ®Google Scholar
• Haupt D. Determination of citalopram enantiomers in human plasma by liquid chromatographic separation on a Chiral-AGP column. J Chromatogr B Biomed Sci Appl 1996; 685: 299–305
   PubMedGoogle Scholar
• El-Gindy A, Emara S, Mesbah M K, Hadad G M. Liquid chromatography determination of citalopram enantiomers using beta-cyclodextrin as a chiral mobile phase additive. J AOAC Int 2006; 89: 65–70
   PubMedGoogle Scholar
• Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444–469
   PubMed Web of Science ®Google Scholar
• Eap C B, Bouchoux G, Amey M, Cochard N, Savary L, Baumann P. Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography mass spectrometry. J Chromatogr Sci 1998; 36: 365–371
   PubMed Web of Science ®Google Scholar
• Salgado-Petinal C, Lamas J P, Garcia-Jares C, Llompart M, Cela R. Rapid screening of selective serotonin re-uptake inhibitors in urine samples using solid-phase microextraction gas chromatography-mass spectrometry. Anal Bioanal Chem 2005; 382: 1351–1359
   PubMed Web of Science ®Google Scholar
• Tournel G, Houdret N, Hedouin V, Deveaux M, Gosset D, Lhermitte M. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Biomed Sci Appl 2001; 761: 147–158
   PubMed Web of Science ®Google Scholar
• Duverneuil C, de la Grandmaison G L, de Mazancourt P, Alvarez J C. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Ther Drug Monit 2003; 25: 565–573
   PubMed Web of Science ®Google Scholar
• Titier K, Castaing N, Scotto-Gomez E, Pehourcq F, Moore N, Molimard M. High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose. Ther Drug Monit 2003; 25: 581–587
   PubMed Web of Science ®Google Scholar
• Kristoffersen L, Bugge A, Lundanes E, Slordal L. Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection. J Chromatogr B Biomed Sci Appl 1999; 734: 229–246
   PubMed Web of Science ®Google Scholar
• Macek J, Ptacek P, Klima J. Rapid determination of citalopram in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 755: 279–285
   PubMed Web of Science ®Google Scholar
• Raggi M A, Pucci V, Mandrioli R, Sabbioni C, Fanali S. Determination of recent antidepressant citalopram in human plasma by liquid chromatography—fluorescence detection. Chromatographia 2003; 57: 273–278
   Web of Science ®Google Scholar
• Meng Q H, Gauthier D. Simultaneous analysis of citalopram and desmethylcitalopram by liquid chromatography with fluorescence detection after solid-phase extraction. Clin Biochem 2005; 38: 282–285
   PubMed Web of Science ®Google Scholar
• Gutteck U, Rentsch K M. Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clin Chem Lab Med 2003; 41: 1571–1579
   PubMed Web of Science ®Google Scholar
• He J, Zhou Z L, Li H D. Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). J Chromatogr B Biomed Sci Appl 2005; 820: 33–39
   PubMed Web of Science ®Google Scholar
• Kollroser M, Schober C. An on-line solid phase extraction—liquid chromatography—tandem mass spectrometry method for the analysis of citalopram, fluvoxamine, and paroxetine in human plasma. Chromatographia 2003; 57: 133–138
   Web of Science ®Google Scholar
• Martinez M A, de la Torre C S, Almarza E. A comparative solid-phase extraction study for the simultaneous determination of fluvoxamine, mianserin, doxepin, citalopram, paroxetine, and etoperidone in whole blood by capillary gas-liquid chromatography with nitrogen-phosphorus detection. J Anal Toxicol 2004; 28: 174–180
   PubMed Web of Science ®Google Scholar
• Wille S MR, Maudens K E, Van Peteghem C H, Lambert W EE. Development of a solid phase extraction for 13 ‘new’ generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. J Chromatogr A 2005; 1098: 19–29
   PubMed Web of Science ®Google Scholar
• McTavish D, Benfield P. Clomipramine—an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990; 39: 136–153
   PubMed Web of Science ®Google Scholar
• Kelly M W, Myers C W. Clomipramine—a tricyclic antidepressant effective in obsessive-compulsive disorder. DICP 1990; 24: 739–744
   PubMedGoogle Scholar
• Glue P, et al. Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999; 66: 152–165
   PubMed Web of Science ®Google Scholar
• Noguchi T, Shimoda K, Takahashi S. Clinical-significance of plasma-levels of clomipramine, its hydroxylated and desmethylated metabolites—prediction of clinical outcome in mood disorders using discriminant-analysis of therapeutic drug-monitoring data. J Affect Disord 1993; 29: 267–279
   PubMed Web of Science ®Google Scholar
• Gorenstein C, Marcourakis T, Bernik M, Lotufo-Neto F. Clomipramine and obsessive-compulsive disorder: serum levels and outcome. Eur Neuropsychopharmacol 1996; 6: 41
   Google Scholar
• Peters M D, Davis S K, Austin L S. Clomipramine—an antiobsessional tricyclic antidepressant. Clin Pharm 1990; 9: 165–178
   PubMedGoogle Scholar
• Francois B, Marquet P, Desachy A, Roustan J, Lachatre G, Gastinne H. Serotonin syndrome due to an overdose of moclobemide and clomipramine—A potentially life-threatening association. Intensive Care Med 1997; 23: 122–124
   PubMed Web of Science ®Google Scholar
• Dardennes R M, Even C, Ballon N, Bange F. Serotonin syndrome caused by a clomipramine-moclobemide interaction. J Clin Psychiatry 1998; 59: 382–383
   PubMed Web of Science ®Google Scholar
• Ferrer-Dufol A, Perez-Aradros C, Murillo E C, Marques-Alamo J M. Fatal serotonin syndrome caused by moclobemide-clomipramine overdose. J Toxicol Clin Toxicol 1998; 36: 31–32
   PubMed Web of Science ®Google Scholar
• Carnis G, Godbillon J, Metayer J P. Determination of clomipramine and desmethyl-clomipramine in plasma or urine by double-radioisotope derivative technique. Clin Chem 1976; 22: 817–823
   PubMed Web of Science ®Google Scholar
• Read G F, Riadfahmy D. Determination of a tricyclic antidepressant, clomipramine (Anafranil), in plasma by a specific radioimmunoassay procedure. Clin Chem 1978; 24: 36–40
   PubMed Web of Science ®Google Scholar
• Bredesen J E, Ellingsen O F, Karlsen J. Rapid isothermal gas-liquid-chromatographic determination of tricyclic anti-depressants in serum with use of a nitrogen-selective detector. J Chromatogr 1981; 204: 361–367
   PubMed Web of Science ®Google Scholar
• Kristinsson J. A gas-chromatographic method for the determination of anti-depressant drugs in human-serum. Acta Pharmacol Toxicol (Copenh) 1981; 49: 390–398
   PubMedGoogle Scholar
• Gupta R N, Stefanec M, Eng F. Determination of tricyclic anti-depressant drugs by gas-chromatography with the use of a capillary column. Clin Biochem 1983; 16: 94–97
   PubMed Web of Science ®Google Scholar
• Lapin A, Karobath M. A sensitive and specific method for the determination of chlorimipramine and desmethylchlorimipramine in plasma using selected ion monitoring with chemical ionization. Biomed Mass Spectrom 1980; 7: 588–591
   PubMedGoogle Scholar
• Sioufi A, Pommier F, Dubois J P. Simultaneous determination of clomipramine and its N-desmethyl metabolite in human whole-blood by capillary gas-chromatography with mass-selective detection. J Chromatogr 1988; 428: 71–80
   PubMed Web of Science ®Google Scholar
• Visser T, Oostelbos M, Toll P. Reliable routine method for the determination of antidepressant drugs in plasma by high-performance liquid-chromatography. J Chromatogr 1984; 309: 81–93
   PubMed Web of Science ®Google Scholar
• Sutfin T A, Dambrosio R, Jusko W J. Liquid-chromatographic determination of 8-tricyclic and tetracyclic antidepressants and their major active metabolites. Clin Chem 1984; 30: 471–474
   PubMed Web of Science ®Google Scholar
• Palego L, Marazziti D, Biondi L, Giannaccini G, Sarno N, Armani A, Lucacchini A, Cassano G B, Dell'Osso L. Simultaneous plasma level analysis of clomipramine, N-desmethylclomipramine, and fluvoxamine by reversed-phase liquid chromatography. Ther Drug Monit 2000; 22: 190–194
   PubMed Web of Science ®Google Scholar
• Altieri I, Pichini S, Pacifici R, Zuccaro P. Improved cleanup procedure for the high-performance liquid-chromatographic assay of clomipramine and its demethylated metabolite in human plasma. J Chromatogr B Biomed Appl 1995; 669: 416–417
   PubMedGoogle Scholar
• Pirola R, Mundo E, Bellodi L, Bareggi S R. Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772: 205–210
   PubMed Web of Science ®Google Scholar
• Weigmann H, Hartter S, Hiemke C. Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. J Chromatogr B Biomed Sci Appl 1998; 710: 227–233
   PubMed Web of Science ®Google Scholar
• Cheer S M, Goa K L. Fluoxetine—A review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61: 81–110
   PubMed Web of Science ®Google Scholar
• Mhanna M J, Bennet J B, Izatt S D. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997; 100: 158–159
   PubMed Web of Science ®Google Scholar
• Messiha F S. Fluoxetine—adverse-effects and drug-drug interactions. J Toxicol Clin Toxicol 1993; 31: 603–630
   PubMed Web of Science ®Google Scholar
• Stokes P E, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19: 1135–1250
   PubMed Web of Science ®Google Scholar
• Spina E, Scordo M G, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17: 517–538
   PubMed Web of Science ®Google Scholar
• Nevado J JB, Salcedo A MC, Llerena M JV. Micellar electrokinetic capillary chromatography for the determination of fluoxetine and its metabolite norfluoxetine in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 769: 261–268
   PubMed Web of Science ®Google Scholar
• Eap C B, Gaillard N, Powell K, Baumann P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography mass spectrometry. J Chromatogr B Biomed Appl 1996; 682: 265–272
   PubMed Web of Science ®Google Scholar
• Ulrich S. Direct stereoselective assay of fluoxetine and norfluoxetine enantiomers in human plasma or serum by two-dimensional gas-liquid chromatography with nitrogen-phosphorus selective detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783: 481–49
   PubMed Web of Science ®Google Scholar
• Pichini S, Pacifici R, Altieri I, Pellegrini M, Zuccaro P. Stereoselective determination of fluoxetine and norfluoxetine enantiomers in plasma samples by high-performance liquid chromatography. J Liq Chromatogr Relat Technol 1996; 19: 1927–1935
   Web of Science ®Google Scholar
• Olsen B A, Wirth D D, Larew J S. Determination of fluoxetine hydrochloride enantiomeric excess using high-performance liquid chromatography with chiral stationary phases. J Pharm Biomed Anal 1998; 17: 623–630
   PubMed Web of Science ®Google Scholar
• Yu H W, Ching C B. Kinetic and equilibrium study of the enantioseparation of fluoxetine on a new beta-cyclodextrin column by high performance liquid chromatography. Chromatographia 2001; 54: 697–702
   Web of Science ®Google Scholar
• Gatti G, Bonomi I, Marchiselli R, Fattore C, Spina E, Scordo G, Pacifici R, Perucca E. Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 375–383
   PubMed Web of Science ®Google Scholar
• Fukushima T, Naka-aki E, Guo X J, Li F M, Vankeirsbilck T, Baeyens W RG, Imai K, Toyo'oka T. Determination of fluoxetine and norfluoxetine in rat brain microdialysis samples following intraperitoneal fluoxetine administration. Anal Chim Acta 2005; 531: 163–163
   Web of Science ®Google Scholar
• Fontanille P, Jourdil N, Villier C, Bessard G. Direct analysis of fluoxetine and norfluoxetine in plasma by gas chromatography with nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 1997; 692: 337–343
   PubMed Web of Science ®Google Scholar
• Ulrich S. Direct stereoselective assay of fluoxetine and norfluoxetine enantiomers in human plasma by two-dimensional gas chromatography with nitrogen-phosphorus selective detection. Pharmacopsychiatry 2002; 35: XI–XI
   Web of Science ®Google Scholar
• Martinez M A, de la Torre C S, Almarza E. A comparative solid-phase extraction study for the simultaneous determination of fluoxetine, amitriptyline, nortriptyline, trimipramine, maprotiline, clomipramine, and trazodone in whole blood by capillary gas-liquid chromatography with nitrogen-phosphorus detection. J Anal Toxicol 2003; 27: 353–358
   PubMed Web of Science ®Google Scholar
• Lefebvre M, Marchand M, Horowitz J M, Torres G. Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography mass spectrometry. Life Sci 1999; 64: 805–811
   PubMed Web of Science ®Google Scholar
• Fathi M, Duparc M T, Morch F, Jayo M, Martin C, Hochstrasser D. Simultaneous determination of fluoxetine, norfluoxetine, paroxetine, sertraline and reboxetine in serum as acetvlated derivatives by gas chromatography-selected ion monitoring mass spectrometry (GC-SIM-MS). Ther Drug Monit 2005; 27: 217–218
   Web of Science ®Google Scholar
• Holladay J W, Dewey M J, Yoo S D. Quantification of fluoxetine and norfluoxetine serum levels by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997; 704: 259–263
   PubMed Web of Science ®Google Scholar
• Alvarez J C, Bothua D, Colignon I, Advenier C, Spreux-Varoquaux O. Determination of fluoxetine and its metabolite norfluoxetine in serum and brain areas using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 707: 175–180
   PubMed Web of Science ®Google Scholar
• Meineke I, Schreeb K, Kress I, Gundert-Remy U. Routine measurement of fluoxetine and norfluoxetine by high-performance liquid chromatography with ultraviolet detection in patients under concomitant treatment with tricyclic antidepressants. Ther Drug Monit 1998; 20: 14–19
   PubMed Web of Science ®Google Scholar
• Molander P, Thomassen A, Kristoffersen L, Greibrokk T, Lundanes E. Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma by temperature-programmed packed capillary liquid chromatography with on-column focusing of large injection volumes. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 77–87
   PubMed Web of Science ®Google Scholar
• Llerena A, Dorado P, Berecz R, Gonzalez A, Norberto M J, de la Rubia A, Caceres M. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783: 25–31
   PubMed Web of Science ®Google Scholar
• Li K M, Thompson M R, McGregor I S. Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 804: 319–326
   PubMed Web of Science ®Google Scholar
• Clausing P, Rushing L G, Newport G D, Bowyer J F. Determination of D-fenfluramine, D-norfenfluramine and fluoxetine in plasma, brain tissue and brain microdialysate using high-performance liquid chromatography after precolumn derivatization with dansyl chloride. J Chromatogr B Biomed Sci Appl 1997; 692: 419–426
   PubMed Web of Science ®Google Scholar
• Raggi M A, Mandrioli R, Casamenti G, Bugamelli F, Volterra V. Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection. J Pharm Biomed Anal 1998; 18: 193–199
   PubMed Web of Science ®Google Scholar
• Vlase L, Imre S, Leucuta S. Determination of fluoxetine and its N-desmethyl metabolite in human plasma by high-performance liquid chromatography. Talanta 2005; 66: 659–663
   PubMed Web of Science ®Google Scholar
• Moraes M O, Lerner F E, Corso G, Bezzerra F AF, Moraes M EA, De Nucci G. Fluoxetine bioequivalence study: Quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. J Clin Pharmacol 1999; 39: 1053–1061
   PubMed Web of Science ®Google Scholar
• Sutherland F CW, Badenhorst D, de Jager A D, Scanes T, Hundt H KL, Swart K J, Hundt A F. Sensitive liquid chromatographic-tandem mass spectrometric method for the determination of fluoxetine and its primary active metabolite norfluoxetine in human plasma. J Chromatogr A 2001; 914: 45–51
   PubMed Web of Science ®Google Scholar
• Li C, Ji Z H, Nan F J, Shao Q X, Liu P, Dai J Y, Zhen J, Yuan H, Xu F, Cui J, Huang B, Zhang M Y, Yu C. Liquid chromatography/tandem mass spectrometry for the determination of fluoxetine and its main active metabolite norfluoxetine in human plasma with deuterated fluoxetine as internal standard. Rapid Commun Mass Spectrom 2002; 16: 1844–1850
   PubMed Web of Science ®Google Scholar
• Green R, Houghton R, Scarth J, Gregory C. Determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by liquid chromatography-tandem mass spectrometry. Chromatographia 2002; 55: S133–S136
   Web of Science ®Google Scholar
• Shen Z Z, Wang S, Bakhtiar R. Enantiomeric separation and quantification of fluoxetine (Prozac (R)) in human plasma by liquid chromatography/tandem mass spectrometry using liquid-liquid extraction in 96-well plate format. Rapid Commun Mass Spectrom 2002; 16: 332–338
   PubMed Web of Science ®Google Scholar
• Cheer S M, Figgitt D R. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. CNS Drugs 2002; 16: 139–144
   PubMed Web of Science ®Google Scholar
• Figgitt D P, McClellan K J. Fluvoxamine—An updated review of its use in the management of adults with anxiety disorders. Drugs 2000; 60: 925–954
   PubMed Web of Science ®Google Scholar
• Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001; 57: 653–658
   PubMed Web of Science ®Google Scholar
• Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72: 835–847
   PubMed Web of Science ®Google Scholar
• Carrasco J L, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005; 59: 1428–1434
   PubMed Web of Science ®Google Scholar
• Hartter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Serum concentrations of fluvoxamine and clinical effects—A prospective open clinical trial. Pharmacopsychiatry 1998; 31: 199–200
   PubMed Web of Science ®Google Scholar
• Preskorn S H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors—An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32: 1–21
   PubMed Web of Science ®Google Scholar
• Devries M H, Raghoebar M, Mathlener I S, Vanharten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14: 493–498
   PubMed Web of Science ®Google Scholar
• Vanharten J, Duchier J, Devissaguet J P, Vanbemmel P, Devries M H, Raghoebar M. Pharmacokinetics of fluvoxamine maleate in patients with liver-cirrhosis after single-dose oral-administration. Clin Pharmacokinet 1993; 24: 177–182
   PubMed Web of Science ®Google Scholar
• Spigset O, Hagg S. Excretion of psychotropic drugs into breast milk—pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9: 111–134
   Web of Science ®Google Scholar
• Goodnick P J. Pharmacokinetic optimization of therapy with newer antidepressants. Clin Pharmacokinet 1994; 27: 307–330
   PubMed Web of Science ®Google Scholar
• Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175–190
   PubMed Web of Science ®Google Scholar
• Labat L, Deveaux M, Dallet P, Dubost J P. Separation of new antidepressants and their metabolites by micellar electrokinetic capillary chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773: 17–23
   PubMed Web of Science ®Google Scholar
• Maurer H H, Bickeboeller-Friedrich J. Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. J Anal Toxicol 2000; 24: 340–347
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Todd K G, Bourin M, Coutts R T, Baker G B. A rapid electron-capture gas chromatographic method for the quantification of fluvoxamine in brain tissue. J Pharmacol Toxicol Methods 1997; 37: 129–133
   PubMed Web of Science ®Google Scholar
• Hostetter A L, Stowe Z N, Cox M, Ritchie J C. A novel system for the determination of antidepressant concentrations in human breast milk. Ther Drug Monit 2004; 26: 47–52
   PubMed Web of Science ®Google Scholar
• Hostetter A, Ritchie J C, Stowe Z N. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry 2000; 48: 1032–1034
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Berzas J J, Contento A M, Cabello M P. Capillary gas chromatographic determination of tamoxifen in the presence of a number of antidepressants in urine. J Sep Sci 2003; 26: 915–922
   Web of Science ®Google Scholar
• Bagli M, Rao M L, Sobanski T, Laux G. Determination of fluvoxamine and paroxetine in human serum with highperformance liquid chromatography and ultraviolet detection. J Liq Chromatogr Relat Technol 1997; 20: 283–295
   Web of Science ®Google Scholar
• Skibinski R, Misztal G, Olajossy M. High performance liquid chromatographic determination of fluvoxamine and paroxetine in plasma. Chem Analityczna 2000; 45: 815–823
   Google Scholar
• Dallet P, Labat L, Richard M, Langlois M H, Dubost J P. A reversed-phase HPLC method development for the separation of new antidepressants. J Liq Chromatogr Relat Technol 2002; 25: 101–111
   Web of Science ®Google Scholar
• Ohkubo T, Shimoyama R, Otani K, Yoshida K, Higuchi H, Shimizu T. High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Anal Sci 2003; 19: 859–864
   PubMed Web of Science ®Google Scholar
• Lucca A, Gentilini G, Lopez-Silva S, Soldarini A. Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography. Ther Drug Monit 2000; 22: 271–276
   PubMed Web of Science ®Google Scholar
• Higashi Y, Matsumura H, Fujii Y. Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. Biomed Chromatogr 2005; 19: 771–776
   PubMed Web of Science ®Google Scholar
• Lamas J P, Salgado-Petinal C, Garcia-Jares C, Llompart M, Cela R, Gomez M. Solid-phase microextraction-gas chromatography-mass spectrometry for the analysis of selective serotonin reuptake inhibitors in environmental water. J Chromatogr A 2004; 1046: 241–247
   PubMed Web of Science ®Google Scholar
• Barri T, Jonsson J A. Supported liquid membrane work-up of blood plasma samples coupled on-line to liquid chromatographic determination of basic antidepressant drugs. Chromatographia 2004; 59: 161–165
   Web of Science ®Google Scholar
• Gutierrez Casares J R, Sanjuan Rodriguez S, Rey Sanchez F, Fernandez de Gatta M M, Dominguez-Gil A, Perez-Rodriguez A. Nocturnal enuresis: imipramine treatment and plasma levels. Eur Psychiat 1996; 11: 342s
   Google Scholar
• Gepertz S, Neveus T. Imipramine for therapy resistant enuresis: A retrospective evaluation. J Urol 2004; 171: 2607–2609
   PubMed Web of Science ®Google Scholar
• Mavissakalian M R, Perel J M, Talbott-Green M, Sloan C. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 1998; 43: 848–854
   PubMed Web of Science ®Google Scholar
• Korzeniewska-Rybicka I, Plaznik A. Analgesic effect of antidepressant drugs. Pharmacol. Biochem. Behav. 1998; 59: 331–338
   PubMed Web of Science ®Google Scholar
• Brosen K, Zeugin T, Meyer U. Role of P450 2D6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49: 609–617
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Tranjohnson T, Davis C M, Leroy A. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect—evaluation of doxepin and imipramine—new data and review. Clin Chem 1988; 34: 863–880
   PubMed Web of Science ®Google Scholar
• Nagy A, Treiber L. Quantitative-determination of imipramine and desipramine in human blood-plasma by direct densitometry of thin-layer chromatograms. J Pharm Pharmacol 1973; 25: 599–603
   PubMed Web of Science ®Google Scholar
• Perel J M, Stiller R L, Glassman A H. Studies on plasma level-effect relationships in imipramine therapy. Commun Psychopharmacol 1978; 2: 429–439
   PubMedGoogle Scholar
• Rasmussen P V, Jensen T S, Sindrup S H, Bach F W. TDM-based imipramine treatment in neuropathic pain. Ther Drug Monit 2004; 26: 352–360
   PubMed Web of Science ®Google Scholar
• Ming M E, Bhawan J, Stefanato C M, McCalmont T H, Cohen L M. Imipramine-induced hyperpigmentation: Four cases and a review of the literature. J Am Acad Dermatol 1999; 40: 159–166
   PubMed Web of Science ®Google Scholar
• Dean C E, Grund F M. Imipramine-associated hyperpigmentation. Ann Pharmacother 2003; 37: 825–828
   PubMed Web of Science ®Google Scholar
• Nykamp D L, Blackmon C L, Schmidt P E, Roberson A G. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005; 39: 543–546
   PubMed Web of Science ®Google Scholar
• Bailey D N, Jatlow P I. Gas-chromatographic analysis for therapeutic concentrations of imipramine and desipramine in plasma, with use of a nitrogen detector. Clin Chem 1976; 22: 1697–1701
   PubMed Web of Science ®Google Scholar
• Chen A G, Wing Y K, Chiu H, Lee S, Chen C N, Chan K. Simultaneous determination of imipramine, desipramine and their 2- and 10-hydroxylated metabolites in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 693: 153–158
   PubMedGoogle Scholar
• Pommier F, Sioufi A, Godbillon J. Simultaneous determination of imipramine and its metabolite desipramine in human plasma by capillary gas chromatography with mass-selective detection. J Chromatogr B Biomed Sci Appl 1997; 703: 147–158
   PubMed Web of Science ®Google Scholar
• Bose D, Martinavarro-Dominguez A, Gil-Agusti M, Carda-Broch S, Durgbanshi A, Capella-Peiro M E, Esteve-Romero J. Therapeutic monitoring of imipramine and desipramine by micellar liquid chromatography with direct injection and electrochemical detection. Biomed Chromatogr 2005; 19: 343–349
   PubMed Web of Science ®Google Scholar
• Eap C B, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit 1999; 21: 166–170
   PubMed Web of Science ®Google Scholar
• Otani K, Mihara K, Okada M, Tanaka O, Kaneko S, Fukushima Y. Prediction of plasma-concentrations of mianserin and desmethylmianserin at steady-state from those after an initial dose of mianserin. Ther Drug Monit 1993; 15: 118–121
   PubMed Web of Science ®Google Scholar
• Wakeling A. Efficacy and side-effects of mianserin, a tetracyclic anti-depressant. Postgrad Med J 1983; 59: 229–231
   PubMed Web of Science ®Google Scholar
• Nawishy S, Hathway N, Turner P. Interactions of anticonvulsant drugs with mianserin and nomifensine. Lancet 1981; 2: 871–872
   PubMed Web of Science ®Google Scholar
• Eap C B, Powell K, Baumann P. Determination of the enantiomers of mianserin and its metabolites in plasma by capillary electrophoresis after liquid-liquid extraction and on-column sample preconcentration. J Chromatogr Sci 1997; 35: 315–320
   Web of Science ®Google Scholar
• Tybring G, Otani K, Kaneko S, Mihara K, Fukushima Y, Bertilsson L. Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Ther Drug Monit 1995; 17: 516–521
   PubMed Web of Science ®Google Scholar
• Vink J, Vanhal H JM. Simplified method for determination of the tetracyclic anti-depressant mianserin in human-plasma using gas-chromatography with nitrogen detection. J Chromatogr 1980; 181: 25–31
   PubMed Web of Science ®Google Scholar
• Wong S HY, Waugh S W, Draz M, Jain N. Liquid-chromatographic determination of 2 antidepressants, trazodone and mianserin, in plasma. Clin Chem 1984; 30: 230–233
   PubMed Web of Science ®Google Scholar
• Hefnawy M M, Aboul-Enein H Y. Fast high-performance liquid chromatographic analysis of mianserin and its metabolites in human plasma using monolithic silica column and solid phase extraction. Anal Chim Acta 2004; 504: 291–297
   Web of Science ®Google Scholar
• Wolf C, Schmid R. Liquid-chromatographic determination of mianserin in plasma by fluorescence detection after online photochemical-reaction. J Pharm Biomed Anal 1990; 8: 1059–1061
   PubMed Web of Science ®Google Scholar
• Chauhan B, Rani S, Guttikar S, Zope A, Jadon N, Padh H. Analytical method development and validation of mianserin hydrochloride and its metabolite in human plasma by LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 823: 69–74
   PubMed Web of Science ®Google Scholar
• Brown L W, Hundt H KL, Swart K J. Automated high-performance liquid-chromatographic method for the determination of mianserin in plasma using electrochemical detection. J Chromatogr 1992; 582: 268–272
   PubMed Web of Science ®Google Scholar
• Spencer C M, Wilde M I. Milnacipran—a review of its use in depression. Drugs 1998; 56: 405–427
   PubMed Web of Science ®Google Scholar
• Delini-Stula A. Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol 2000; 15: 255–260
   PubMed Web of Science ®Google Scholar
• Puozzo C, Lens S, Reh C, Michaelis K, Rosillon D, Deroubaix X, Deprez D. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005; 44: 977–988
   PubMed Web of Science ®Google Scholar
• Puozzo C, Filaquier C, Zorza G. Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 806: 221–228
   PubMed Web of Science ®Google Scholar
• Puozzo C, Albin H, Vincon G, Deprez D, Raymond J M, Amouretti M. Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 1998; 23: 273–279
   PubMed Web of Science ®Google Scholar
• Morishita S, Arita S. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Eur Psychiatry 2003; 18: 418–420
   PubMed Web of Science ®Google Scholar
• Puozzo C, Pozet N, Deprez D, Baille P, Ung H L, Zech P P. Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab Pharmacokinet 1998; 23: 280–286
   PubMed Web of Science ®Google Scholar
• Yoshida K, Higuchi H, Takahashi H, Shimizu T. Elevation of blood pressure induced by high-dose milnacipran. Hum Psychopharmacol 2002; 17: 431–431
   PubMed Web of Science ®Google Scholar
• Alves T CD, de Andrade A G. Hypertension induced by regular doses of milnacipran: A case report. Pharmacopsychiatry 2007; 40: 41–42
   Web of Science ®Google Scholar
• Shinozuka T, Terada M, Tanaka E. Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method. Forensic Sci Int 2006; 162: 108–112
   PubMed Web of Science ®Google Scholar
• Holm K J, Markham A. Mirtazapine—A review of its use in major depression. Drugs 1999; 57: 607–631
   PubMed Web of Science ®Google Scholar
• Fawcett J, Barkin R L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267–285
   PubMed Web of Science ®Google Scholar
• Timmer C J, Sitsen J MA, Delbressine L P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461–474
   PubMed Web of Science ®Google Scholar
• Grasmader K, Verwohlt P L, Kuhn K U, Frahnert C, Hiemke C, Dragicevic A, von Widdern O, Zobel A, Maier W, Rao M L. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry 2005; 38: 113–117
   PubMed Web of Science ®Google Scholar
• Puzantian T. Mirtazapine, an antidepressant. Am J Health Syst Pharm 1998; 55: 44–49
   PubMed Web of Science ®Google Scholar
• Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17: 251–264
   PubMed Web of Science ®Google Scholar
• Ruwe F JL, Smulders R A, Kleijn H J, Hartmans H LA, Sitsen J MA. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2001; 16: 449–459
   PubMed Web of Science ®Google Scholar
• Sennef C, Timmer C J, Sitsen J AA. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2003; 18: 91–101
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Pucci V, Sabbioni C, Bartoletti C, Fanali S, Raggi M A. Enantioselective determination of the novel antidepressant mirtazapine and its active demethylated metabolite in human plasma by means of capillary electrophoresis. J Chromatogr A 2004; 1051: 253–260
   PubMed Web of Science ®Google Scholar
• Romiguieres T, Pehourcq F, Matoga M, Begaud B, Jarry C. Determination of mirtazapine and its demethyl metabolite in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 775: 163–168
   PubMed Web of Science ®Google Scholar
• Morgan P E, Tapper J, Spencer E P. Rapid and sensitive analysis of mirtazapine & normirtazapine in plasma/serum by HPLC with fluorescence detection. J Psychopharmacol 2002; 16: A64–A64
   Web of Science ®Google Scholar
• Shams M, Hartter S, Hiemke C. Column switching and high performance liquid chromatography (HPLC) with fluorescence detection for automated analysis of venlafaxine, mirtazapine and demethylated metabolites in blood serum or plasma. Pharmacopsychiatry 2002; 35: X–X
   Web of Science ®Google Scholar
• Ptacek P, Klima J, Macek J. Determination of mirtazapine in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 794: 323–328
   PubMed Web of Science ®Google Scholar
• Pistos C, Koutsopoulou M, Panderi I. A validated liquid chromatographic tandem mass spectrometric method for the determination of mirtazapine and demethylmirtazapine in human plasma: application to a pharmacokinetic study. Anal Chim Acta 2004; 514: 15–26
   Web of Science ®Google Scholar
• Paus E, Jonzier-Perey M, Cochard N, Eap C B, Baumann P. Chirality in the new generation of antidepressants—Stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit 2004; 26: 366–374
   PubMed Web of Science ®Google Scholar
• de Santana F JM, de Oliveira A RM, Bonato P S. Chiral liquid chromatographic determination of mirtazapine in human plasma using two-phase liquid-phase microextraction for sample preparation. Anal Chim Acta 2005; 549: 96–103
   Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Ghedini N, Bartoletti C, Fanali S, Raggi M A. Determination of the antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection. Anal Chim Acta 2006; 556: 281–288
   Web of Science ®Google Scholar
• Paterson S, Cordero R, Burlinson S. Screening and semi-quantitative analysis of postmortem blood for basic drugs using gas chromatography/ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 323–330
   PubMed Web of Science ®Google Scholar
• Bickeboeller-Friedrich J, Maurer H H. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther Drug Monit 2001; 23: 61–70
   PubMed Web of Science ®Google Scholar
• Dodd S, Burrows G D, Norman T R. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 748: 439–443
   PubMed Web of Science ®Google Scholar
• Wagstaff A J, Cheer S M, Matheson A J. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002; 62: 655–703
   PubMed Web of Science ®Google Scholar
• Wagstaff A J, Cheer S M, Matheson A J, Ormrod D, Goa K L. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs 2002; 16: 425–434
   PubMed Web of Science ®Google Scholar
• Caley C F, Weber S S. Paroxetine- a selective reuptake inhibiting antidepressant. Ann Pharmacother 1993; 27: 1212–1222
   PubMed Web of Science ®Google Scholar
• Gunasekara N S, Noble S, Benfield P. Paroxetine-an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55: 85–120
   PubMed Web of Science ®Google Scholar
• Lai C T, Gordon E S, Kennedy S H, Bateson A N, Coutts R T, Baker G B. Determination of paroxetine levels in human plasma using gas chromatography with electron-capture detection. J Chromatogr B Biomed Sci Appl 2000; 749: 275–279
   PubMed Web of Science ®Google Scholar
• Leis H J, Windischhofer W, Raspotnig G, Fauler G. Stable isotope dilution negative ion chemical ionization gas chromatography-mass spectrometry for the quantitative analysis of paroxetine in human plasma. J Mass Spectrom 2001; 36: 923–928
   PubMed Web of Science ®Google Scholar
• Leis H J, Windischhofer W, Fauler G. Improved sample, preparation for the quantitative analysis of paroxetine in human plasma by stable isotope dilution negative ion chemical ionisation gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 779: 353–357
   PubMed Web of Science ®Google Scholar
• Foglia J P, Sorisio D, Kirshner M, Pollock B G. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997; 693: 147–151
   PubMed Web of Science ®Google Scholar
• Zainaghi I A, Lanchote V L, Queiroz R HC. Determination of paroxetine in geriatric depression by high-performance liquid chromatography. Pharmacol Res 2003; 48: 217–221
   PubMed Web of Science ®Google Scholar
• Shin J G, Kim K A, Yoon Y R, Cha I J, Kim Y H, Shin S G. Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma. J Chromatogr B Biomed Sci Appl 1998; 713: 452–456
   PubMed Web of Science ®Google Scholar
• Lopez-Calull C, Dominguez N. Determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies. J Chromatogr B Biomed Sci Appl 1999; 724: 393–398
   PubMed Web of Science ®Google Scholar
• Schatz D S, Saria A. Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection. Pharmacology 2000; 60: 51–56
   PubMed Web of Science ®Google Scholar
• Zhu Z M, Neirinck L. High-performance liquid chromatography-mass spectrometry method for the determination of paroxetine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 780: 295–300
   PubMed Web of Science ®Google Scholar
• Segura M, Ortuno J, Farre M, Pacifici R, Pichini S, Joglar J, Segura J, de la Torre R. Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. Rapid Commun Mass Spectrom 2003; 17: 1455–1461
   PubMed Web of Science ®Google Scholar
• Vivekanand V V, Kumar V R, Mohakhud P K, Reddy G O. Enantiomeric separation of the key intermediate of paroxetine using chiral chromatography. J Pharm Biomed Anal 2003; 33: 803–809
   PubMed Web of Science ®Google Scholar
• Weng N D, Eerkes A. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. Biomed Chromatogr 2004; 18: 28–36
   PubMed Web of Science ®Google Scholar
• DeVane C L, Liston H L, Markowitz J S. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247–1266
   PubMed Web of Science ®Google Scholar
• Mauri M C, Laini V, Cerveri G, Scalvini M E, Volonteri L S, Regispani F, Malvini L, Manfre S, Boscati L, Panza G. Clinical outcome and tolerability of sertraline in major depression—A study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 597–601
   PubMed Web of Science ®Google Scholar
• Lucangioli S E, Hermida L G, Tripodi V P, Rodriguez V G, Lopez E E, Rouge P D, Carducci C N. Analysis of cis-trans isomers and enantiomers of sertraline by cyclodextrin-modified micellar electrokinetic chromatography. J Chromatogr A 2000; 871: 207–215
   PubMed Web of Science ®Google Scholar
• Rogowsky D, Marr M, Long G, Moore C. Determination of sertraline and desmethylsertraline in human serum using copolymeric bonded-phase extraction, liquid-chromatography and gas-chromatography mass-spectrometry. J Chromatogr B Biomed Appl 1994; 655: 138–141
   PubMed Web of Science ®Google Scholar
• Eap C B, Bouchoux G, Amey M, Cochard N, Savary L, Baumann P. Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography mass spectrometry. J Chromatogr Sci 1998; 36: 365–371
   PubMed Web of Science ®Google Scholar
• Kim K M, Jung B H, Choi M H, Woo J S, Paeng K J, Chung B C. Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 769: 333–339
   PubMed Web of Science ®Google Scholar
• Casamenti G, Mandrioli R, Sabbioni C, Bugamelli F, Volterra V, Raggi M A. Development of an HPLC method for the toxicological screening of central nervous system drugs. J Liq Chromatogr Relat Technol 2000; 23: 1039–1059
   Web of Science ®Google Scholar
• Jain D S, Sanyal M, Subbaiah G, Pande U C, Shrivastav P. Rapid and sensitive method for the determination of sertraline in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 69–74
   PubMed Web of Science ®Google Scholar
• He L J, Feng F, Wu J. Determination of sertraline in human plasma by high-performance liquid chromatography-electrospray ionization mass sprectrometry and method validation. J Chromatogr Sci 2005; 43: 532–535
   PubMed Web of Science ®Google Scholar
• Morton W A, Sonne S C, Verga M A. Venlafaxine—a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387–395
   PubMed Web of Science ®Google Scholar
• Reis M, Lundmark J, Bjork H, Bengtsson F. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002; 24: 545–553
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine. Depress Anxiety 2000; 12: 30–44
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brosen K, Dahl M L, Gram L F, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173–192
   PubMed Web of Science ®Google Scholar
• Roseboom P H, Kalin N H. Neuropharmacology of venlafaxine. Depress Anxiety 2000; 12: 20–29, (Suppl 1)
   PubMed Web of Science ®Google Scholar
• Burnett F E, Dinan T G. Venlafaxine. Pharmacology and therapeutic potential in the treatment of depression. Hum Psychopharmacol 1998; 13: 153–162
   Web of Science ®Google Scholar
• Rudaz S, Calleri E, Geiser L, Cherkaoui S, Prat J, Veuthey J L. Infinite enantiomeric resolution of basic compounds using highly sulfated cyclodextrin as chiral selector in capillary electrophoresis. Electrophoresis 2003; 24: 2633–2641
   PubMed Web of Science ®Google Scholar
• Martinez M A, de la Torre C S, Almarza E. Simultaneous determination of viloxazine, venlafaxine, imipramine, desipramine, sertraline, and amoxapine in whole blood: Comparison of two extraction/cleanup procedures for capillary gas chromatography with nitrogen-phosphorus detection. J Anal Toxicol 2003; 27: 8A–8A
   Web of Science ®Google Scholar
• Martinez M A, de la Torre C S, Almarza E. Simultaneous determination of viloxazine, venlafaxine, imipramine, desipramine, sertraline, and amoxapine in whole blood: Comparison of two extraction/cleanup procedures for capillary gas chromatography with nitrogen-phosphorus detection. J Anal Toxicol 2002; 26: 296–302
   PubMed Web of Science ®Google Scholar
• Hicks D R, Wolaniuk D, Russell A, Cavanaugh N, Kraml M. A high-performance liquid-chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological-fluids. Ther Drug Monit 1994; 16: 100–107
   PubMed Web of Science ®Google Scholar
• Matoga M, Pehourcq F, Titier K, Dumora F, Jarry C. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma—application to management of acute intoxications. J Chromatogr B Biomed Sci Appl 2001; 760: 213–218
   PubMed Web of Science ®Google Scholar
• Raut B B, Kolte B L, Deo A A, Bagool M A, Shinde D B. A rapid and sensitive HPLC method for the determination of venlafaxine and O-desmethylvenlafaxine in human plasma with UV detection. J Liq Chromatogr Relat Technol 2003; 26: 1297–1313
   Web of Science ®Google Scholar
• Waschgler R, Moll W, Konig P, Conca A. Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis. Int J Clin Pharmacol Ther 2004; 42: 724–728
   PubMed Web of Science ®Google Scholar
• Bhatt J, Jangid A, Venkatesh G, Subbaiah G, Singh S. Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 75–81
   PubMed Web of Science ®Google Scholar
• Barnes J, Anderson L A, Phillipson J D. St. John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583–600
   PubMed Web of Science ®Google Scholar
• Zanoli P. Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Rev 2004; 10: 203–218
   PubMedGoogle Scholar
• Caccia S. Antidepressant-like components of hypericum perforatum extracts: an overview of their pharmacokinetics and metabolism. Curr Drug Metab 2005; 6: 531–543
   PubMed Web of Science ®Google Scholar
• Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: A ‘modern’ herbal antidepressant-pharmacokinetics of active ingredients. Clin Pharmacokinet 2006; 45: 449–468
   PubMed Web of Science ®Google Scholar
• Nathan P J. Hypericum perforatum (St. John's wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 2001; 15: 47–54
   PubMed Web of Science ®Google Scholar
• Muller W E. Current St. John's wort research from mode of action to clinical efficacy. Pharmacol Res 2003; 47: 101–109
   PubMed Web of Science ®Google Scholar
• Linde K, Mulrow C D, Berner M, Egger M. St. John's Wort for depression. Cochrane Database Syst Rev 2005; 2, CD000448
   Google Scholar
• Pellati F, Benvenuti S, Melegari M. Chromatographic performance of a new polar poly(ethylene glycol) bonded phase for the phytochemical analysis of Hypericum perforatum L. J Chromatogr A 2005; 1088: 205–217
   PubMed Web of Science ®Google Scholar
• Biber A, Fischer H, Romer A, Chatterjee S S. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31: 36–43
   PubMed Web of Science ®Google Scholar
• Schulz H U, Schurer M, Bassler D, Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung 2005; 55: 15–22
   PubMed Web of Science ®Google Scholar
• Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum-perforatum extract Li-160 in healthy-volunteers. Nervenheilkunde 1993; 12: 331–338
   Web of Science ®Google Scholar
• Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40: 2087–2093
   PubMed Web of Science ®Google Scholar
• Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression—An overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253–258
   PubMed Web of Science ®Google Scholar
• DeSmet P, Nolen W A. St. John's wort as an antidepressant—Longer term studies are needed before it can be recommended in major depression. BMJ 1996; 313: 241–242
   PubMedGoogle Scholar
• Study shows St. John's wort ineffective for major depression. FDA Consum. 2002; 36: 8
   Google Scholar
• Davidson J RT, et al. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder—A randomized controlled trial. JAMA 2002; 287: 1807–1814
   PubMed Web of Science ®Google Scholar
• Linde K, Berner M, Egger M, Mulrow C. St. John's wort for depression—Meta-analysis of randomised controlled trials. Br J Psychiatry 2005; 186: 99–107
   PubMed Web of Science ®Google Scholar
• Pilkington K, Boshnakova A, Richardson J. St. John's wort for depression: time for a different perspective?. Complement Ther Med 2006; 14: 268–281
   PubMed Web of Science ®Google Scholar
• Randlov C, Mehlsen J, Thomsen C F, Hedman C, von Fircks H, Winther K. The efficacy of St. John's wort in patients with minor depressive symptoms or dysthymia—a double-blind placebo-controlled study. Phytomedicine 2006; 13: 215–221
   PubMed Web of Science ®Google Scholar
• Izzo A A. Drug interactions with St. John's wort (hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42: 139–148
   PubMed Web of Science ®Google Scholar
• Trautmann-Sponsel R D, Dienel A. Safety of hypericum extract in mildly to moderately depressed outpatients—A review based on data from three randomized, placebo-controlled trials. J Affect Disord 2004; 82: 303–307
   PubMed Web of Science ®Google Scholar
• Demiroglu Y Z, Yeter T T, Boga C, Ozdogu H, Kizilkilic E, Bal N, Tuncer I, Arslan H. Bone marrow necrosis: a rare complication of herbal treatment with Hypericum perforatum (St. John's wort). Acta Medica 2005; 48: 91–94
   Google Scholar
• Mannel M. Drug interactions with St. John's wort—mechanisms and clinical implications. Drug Saf 2004; 27: 773–797
   PubMed Web of Science ®Google Scholar
• Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006; 62: 225–233
   PubMed Web of Science ®Google Scholar
• Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338–345
   PubMed Web of Science ®Google Scholar
• Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer H H, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 2003; 55: 203–211
   PubMed Web of Science ®Google Scholar
• Jiang X M, Williams K M, Liauw W S, Ammit A J, Roufogalis B D, Duke C C, Day R O, McLachlan A J. Effect of St. John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592–599
   PubMed Web of Science ®Google Scholar
• Ruschitzka F, Meier P J, Turina M, Luscher T F, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548–549
   PubMed Web of Science ®Google Scholar
• Klier C M, Schafer M R, Schmid-Siegel B, Lenz G, Mannel M. St. John's wort (hypericum perforatum)—Is it safe during breastfeeding?. Pharmacopsychiatry 2002; 35: 29–30
   PubMed Web of Science ®Google Scholar
• Klier C M, Schmid-Siegel B, Schafer M R, Lenz G, Saria A, Lee A, Zernig G. St. John's wort (hypericum perforatum) and breastfeeding: Plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants. J Clin Psychiatry 2006; 67: 305–309
   PubMed Web of Science ®Google Scholar
• Liebes L, Mazur Y, Freeman D, Lavie D, Lavie G, Kudler N, Mendoza S, Levin B, Hochster H, Meruelo D. A method for the quantitation of hypericin, an antiviral agent, in biological-fluids by high-performance liquid-chromatography. Anal Biochem 1991; 195: 77–85
   PubMed Web of Science ®Google Scholar
• Chi J D, Franklin M. Determination of hypericin in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 724: 195–198
   PubMed Web of Science ®Google Scholar
• Bauer S, Stormer E, Graubaum H J, Roots I. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001; 765: 29–35
   PubMed Web of Science ®Google Scholar
• Cui Y Y, Gurley B, Ang C YW, Leakey J. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 780: 129–135
   PubMed Web of Science ®Google Scholar
• Pirker R, Huck C W, Bonn G K. Simultaneous determination of hypericin and hyperforin in human plasma and serum using liquid-liquid extraction, high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777: 147–153
   PubMed Web of Science ®Google Scholar
• Riedel K D, Rieger K, Martin-Facklam M, Mikus G, Haefeli W E, Burhenne J. Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 27–33
   PubMed Web of Science ®Google Scholar
• Draves A H, Walker S E. Determination of hypericin and pseudohypericin in pharmaceutical preparations by liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 2000; 749: 57–66
   PubMedGoogle Scholar
• Li W K, Fitzloff J F. High performance liquid chromatographic analysis of St. John's wort with photodiode array detection. J Chromatogr B Biomed Sci Appl 2001; 765: 99–105
   PubMed Web of Science ®Google Scholar
• Jensen A G, Hansen S H. Separation of hypericins and hyperforins in extracts of Hypericum perforatum L. using non-aqueous capillary electrophoresis with reversed electro-osmotic flow. J Pharm Biomed Anal 2002; 27: 167–176
   PubMed Web of Science ®Google Scholar
• Ganzera M, Zhao J, Khan I A. Hypericum perforatum—Chemical profiling and quantitative results of St. John's Wort products by an improved high-performance liquid chromatography method. J Pharm Sci 2002; 91: 623–630
   PubMed Web of Science ®Google Scholar
• Ruckert U, Eggenreich K, Wintersteiger R, Wurglics M, Likussar W, Michelitsch A. Development of a high-performance liquid chromatographic method with electrochemical detection for the determination of hyperforin. J Chromatogr A 2004; 1041: 181–185
   PubMed Web of Science ®Google Scholar